TERN · Insider Trading
Terns Pharmaceuticals, Inc. Common Stock
Every open-market purchase and sale reported by TERN officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-05-05 | Heather D Turner | Director | D | −110,697 deriv. | — |
| 2026-05-05 | Jeffrey B Kindler | Director | D | −208,505 deriv. | — |
| 2026-05-05 | Jill M. Quigley | Director | D | −147,309 deriv. | — |
| 2026-05-05 | David A Fellows | Director | D | −221,136 deriv. | — |
| 2026-05-05 | Amy L. Burroughs | Chief Executive Officer | MIXED | −304,933 | −$16.16M |
| 2026-05-05 | Robert Azelby | Director | D | −91,697 deriv. | — |
| 2026-05-05 | Emil Kuriakose | Chief Medical Officer | MIXED | −106,515 | −$5.65M |
| 2026-05-05 | Andrew Gengos | Chief Financial Officer | MIXED | −109,253 | −$5.79M |
| 2026-05-05 | Radhika Tripuraneni | Director | D | −190,030 deriv. | — |
| 2026-04-02 | Emil Kuriakose | Chief Medical Officer | Sell | −942 | −$49.69K |
| 2026-03-17 | Amy L. Burroughs | Chief Executive Officer | MIXED | — | −$613.44K |
| 2026-02-18 | Amy L. Burroughs | Chief Executive Officer | MIXED | — | −$503.91K |
| 2026-02-02 | Heather D Turner | Director | A | +1,697 deriv. | — |
| 2026-02-02 | Robert Azelby | Director | A | +1,697 deriv. | — |
| 2026-02-02 | Jill M. Quigley | Director | A | +1,697 deriv. | — |
| 2026-02-02 | David A Fellows | Director | A | +2,828 deriv. | — |
| 2026-02-02 | Radhika Tripuraneni | Director | A | +1,697 deriv. | — |
| 2026-02-02 | Jeffrey B Kindler | Director | A | +1,697 deriv. | — |
| 2026-01-16 | Andrew Gengos | Chief Financial Officer | A | +68,750 | — |
| 2026-01-16 | Emil Kuriakose | Chief Medical Officer | A | +56,250 | — |
| 2026-01-16 | Amy L. Burroughs | Chief Executive Officer | MIXED | +150,000 | −$2.23M |
| 2026-01-06 | Emil Kuriakose | Chief Medical Officer | Sell | −1,155 | −$44.55K |
| 2026-01-06 | Amy L. Burroughs | Chief Executive Officer | MIXED | +100,212 | −$2.62M |
| 2025-11-05 | Jill M. Quigley | Director | MIXED | — | −$214.80K |
| 2025-10-02 | Emil Kuriakose | Chief Medical Officer | Sell | −944 | −$7.41K |
| 2025-07-03 | Emil Kuriakose | Chief Medical Officer | Sell | −853 | −$3.64K |
| 2025-06-30 | Andrew Gengos | Chief Financial Officer | Buy | +10,000 | +$39.28K |
| 2025-06-25 | Amy L. Burroughs | Chief Executive Officer | Buy | +23,314 | +$90.23K |
| 2025-06-16 | Andrew Gengos | Chief Financial Officer | Buy | +15,000 | +$57.08K |
| 2025-06-12 | Jill M. Quigley | Director | A | +45,000 deriv. | — |
| 2025-06-12 | Hongbo Lu | Director | A | +45,000 deriv. | — |
| 2025-06-12 | Jeffrey B Kindler | Director | A | +45,000 deriv. | — |
| 2025-06-12 | Radhika Tripuraneni | Director | A | +45,000 deriv. | — |
| 2025-06-12 | Heather D Turner | Director | A | +45,000 deriv. | — |
| 2025-06-12 | David A Fellows | Director | A | +45,000 deriv. | — |
| 2025-04-02 | Emil Kuriakose | Chief Medical Officer | Sell | −952 | −$2.37K |
| 2025-02-25 | Andrew Gengos | Chief Financial Officer | A | +750,000 deriv. | — |
| 2025-02-24 | Robert Azelby | Director | A | +90,000 deriv. | — |
| 2025-02-03 | Hongbo Lu | Director | A | +10,657 deriv. | — |
| 2025-02-03 | Radhika Tripuraneni | Director | A | +10,657 deriv. | — |
| 2025-02-03 | Jeffrey B Kindler | Director | A | +10,657 deriv. | — |
| 2025-02-03 | Amy L. Burroughs | Chief Executive Officer | Buy | +510 | +$2.61K |
| 2025-02-03 | Jill M. Quigley | Director | A | +10,657 deriv. | — |
| 2025-02-03 | David A Fellows | Director | A | +18,650 deriv. | — |
| 2025-02-03 | Melita Sun Jung | Chief Business Officer | Buy | +2,250 | +$11.50K |
| 2025-02-03 | Emil Kuriakose | Chief Medical Officer | A | +485,000 deriv. | — |
| 2025-01-06 | Jill M. Quigley | Director | Sell | −15,000 | −$86.46K |
| 2025-01-06 | Emil Kuriakose | Chief Medical Officer | Sell | −4,481 | −$25.61K |
| 2025-01-06 | Mark J. Vignola | Chief Financial Officer | Sell | −17,188 | −$99.02K |
| 2024-12-16 | Emil Kuriakose | Chief Medical Officer | A | +120,000 deriv. | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| Hongbo Lu | Director | 476,190 | $25.21M |
| Mark J. Vignola | Chief Financial Officer | 83,811 | $4.44M |
| Jill M. Quigley | Director | 24,520 | $1.30M |
| Melita Sun Jung | Chief Business Officer | 2,250 | $119.14K |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the TERN quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.